| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
30 |
S2 |
p. xi
|
artikel
|
| 2 |
Activity of larotrectinib in TRK fusion lung cancer
|
Drilon, A.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 3 |
ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer
|
Senan, S.
|
|
|
30 |
S2 |
p. ii25
|
artikel
|
| 4 |
Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade
|
Nie, W.
|
|
|
30 |
S2 |
p. ii62
|
artikel
|
| 5 |
Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial
|
Passaro, A.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 6 |
A Mendelian randomization study of the effects of Crohn’s disease on lung cancer
|
Liu, J.
|
|
|
30 |
S2 |
p. ii18
|
artikel
|
| 7 |
A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer
|
Han, B.
|
|
|
30 |
S2 |
p. ii62
|
artikel
|
| 8 |
A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation
|
Manca, P.
|
|
|
30 |
S2 |
p. ii8
|
artikel
|
| 9 |
A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy
|
Roengvoraphoj, O.
|
|
|
30 |
S2 |
p. ii37
|
artikel
|
| 10 |
Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer
|
Lian, Z.
|
|
|
30 |
S2 |
p. ii50
|
artikel
|
| 11 |
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial
|
Gelsomino, F.
|
|
|
30 |
S2 |
p. ii67-ii68
|
artikel
|
| 12 |
An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
|
Spicer, J.
|
|
|
30 |
S2 |
p. ii65-ii66
|
artikel
|
| 13 |
A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
|
Planchard, D.
|
|
|
30 |
S2 |
p. ii66-ii67
|
artikel
|
| 14 |
A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
|
Paik, P.
|
|
|
30 |
S2 |
p. ii66
|
artikel
|
| 15 |
Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients
|
Calabuig Fariñas, S.
|
|
|
30 |
S2 |
p. ii9
|
artikel
|
| 16 |
A prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC
|
Bhowal, S.
|
|
|
30 |
S2 |
p. ii35
|
artikel
|
| 17 |
Assessment of toxicity and clinical outcomes with SBRT in lung metastases: A single institute experience
|
Pareek, V.
|
|
|
30 |
S2 |
p. ii69
|
artikel
|
| 18 |
Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)
|
Saavedra Serrano, C.
|
|
|
30 |
S2 |
p. ii57-ii58
|
artikel
|
| 19 |
A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant
|
Qu, J.
|
|
|
30 |
S2 |
p. ii51
|
artikel
|
| 20 |
Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice
|
Hou, T.F.
|
|
|
30 |
S2 |
p. ii6
|
artikel
|
| 21 |
Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
|
Liang, L.
|
|
|
30 |
S2 |
p. ii4
|
artikel
|
| 22 |
Baseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80
|
Leleu, O.
|
|
|
30 |
S2 |
p. ii14
|
artikel
|
| 23 |
Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)
|
Corral de la Fuente, E.
|
|
|
30 |
S2 |
p. ii61-ii62
|
artikel
|
| 24 |
Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials
|
Nie, W.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 25 |
Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
|
Califano, R.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 26 |
Brigatinib experience on the ALK project
|
Gomes, F.
|
|
|
30 |
S2 |
p. ii53
|
artikel
|
| 27 |
Can a BALF profile distinguish hot vs cold lung tumors?
|
Domagala-Kulawik, J.
|
|
|
30 |
S2 |
p. ii11-ii12
|
artikel
|
| 28 |
Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience
|
Harbegue, K.
|
|
|
30 |
S2 |
p. ii35
|
artikel
|
| 29 |
Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis
|
Raniszewska, A.
|
|
|
30 |
S2 |
p. ii69
|
artikel
|
| 30 |
Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy
|
Galli, G.
|
|
|
30 |
S2 |
p. ii56
|
artikel
|
| 31 |
Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis
|
Addeo, A.
|
|
|
30 |
S2 |
p. ii57
|
artikel
|
| 32 |
Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)
|
Horn, L.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 33 |
Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs
|
Passaro, A.
|
|
|
30 |
S2 |
p. ii54
|
artikel
|
| 34 |
Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis
|
Landre, T.
|
|
|
30 |
S2 |
p. ii60
|
artikel
|
| 35 |
Clinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival
|
Zhang, B.
|
|
|
30 |
S2 |
p. ii53-ii54
|
artikel
|
| 36 |
Clinical significance of ROS1 5’ deletions detected by FISH and response to crizotinib
|
Dall’Olio, F.G.
|
|
|
30 |
S2 |
p. ii54-ii55
|
artikel
|
| 37 |
Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer
|
Ge, H.
|
|
|
30 |
S2 |
p. ii3
|
artikel
|
| 38 |
Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients
|
Kho, C.Y.X.
|
|
|
30 |
S2 |
p. ii54
|
artikel
|
| 39 |
Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population
|
Shen, Y.
|
|
|
30 |
S2 |
p. ii11
|
artikel
|
| 40 |
Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer
|
Zhang, Q.
|
|
|
30 |
S2 |
p. ii4
|
artikel
|
| 41 |
Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy
|
Bushra, S.
|
|
|
30 |
S2 |
p. ii21
|
artikel
|
| 42 |
Comparison of three different gene panels for determination of tumor mutational burden by next generation sequencing
|
Pappesch, R.
|
|
|
30 |
S2 |
p. ii9
|
artikel
|
| 43 |
Comprehensive profiling of genomic and TCR repertoire in localized stage lung adenocarcinomas from a prospective cohort study
|
Chen, K.
|
|
|
30 |
S2 |
p. ii26
|
artikel
|
| 44 |
Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients
|
Lee, K.A.
|
|
|
30 |
S2 |
p. ii19
|
artikel
|
| 45 |
Correlation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC
|
Gianoncelli, L.
|
|
|
30 |
S2 |
p. ii57
|
artikel
|
| 46 |
Correlation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma
|
Tamura, N.
|
|
|
30 |
S2 |
p. ii2
|
artikel
|
| 47 |
Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer
|
Son, C.
|
|
|
30 |
S2 |
p. ii2
|
artikel
|
| 48 |
Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience
|
Krpina, K.
|
|
|
30 |
S2 |
p. ii52
|
artikel
|
| 49 |
Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study
|
Rounis, K.
|
|
|
30 |
S2 |
p. ii61
|
artikel
|
| 50 |
Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
|
Shaw, A.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 51 |
CT image standardization is superior to larger but heterogeneous data for robust radiomic models
|
Vuong, D.
|
|
|
30 |
S2 |
p. ii20
|
artikel
|
| 52 |
Detection and clinicopathologic features of ctDNA in T790M-positive advanced lung adenocarcinomas patients after failure of treatment with first- and second-generation EGFR-TKIs
|
He, W.
|
|
|
30 |
S2 |
p. ii52
|
artikel
|
| 53 |
Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis
|
Li, C.C.
|
|
|
30 |
S2 |
p. ii13
|
artikel
|
| 54 |
Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer
|
Lee, S.C.
|
|
|
30 |
S2 |
p. ii75
|
artikel
|
| 55 |
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC
|
Mazzaschi, G.
|
|
|
30 |
S2 |
p. ii1
|
artikel
|
| 56 |
Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
|
Domagala-Kulawik, J.
|
|
|
30 |
S2 |
p. ii10
|
artikel
|
| 57 |
Dynamic changes of patelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC
|
Zhou, F.
|
|
|
30 |
S2 |
p. ii61
|
artikel
|
| 58 |
Editorial board
|
|
|
|
30 |
S2 |
p. ii-iii
|
artikel
|
| 59 |
Education and lung cancer: A Mendelian randomisation study
|
Zhou, H.
|
|
|
30 |
S2 |
p. ii18
|
artikel
|
| 60 |
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)
|
Angelats, L.
|
|
|
30 |
S2 |
p. ii53
|
artikel
|
| 61 |
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
|
Reinmuth, N.
|
|
|
30 |
S2 |
p. ii77
|
artikel
|
| 62 |
Effect of surgical treatment on the survival in patients with malignant pleural mesothelioma
|
Baez-Saldana, R.
|
|
|
30 |
S2 |
p. ii72
|
artikel
|
| 63 |
Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence
|
Roitberg, F.S.R.
|
|
|
30 |
S2 |
p. ii37
|
artikel
|
| 64 |
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
|
Cho, B.C.
|
|
|
30 |
S2 |
p. ii79-ii80
|
artikel
|
| 65 |
Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO
|
Grohe, C.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 66 |
Efficacy of 150kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro
|
Weinberg, U.
|
|
|
30 |
S2 |
p. ii72
|
artikel
|
| 67 |
Efficacy of tyrosine kinase inhibitors (TKIs) in advanced lung adenosquamous carcinoma
|
Hu, M.
|
|
|
30 |
S2 |
p. ii56
|
artikel
|
| 68 |
EGFR & PD L1: An (im)perfect union
|
Batra, U.
|
|
|
30 |
S2 |
p. ii51-ii52
|
artikel
|
| 69 |
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
|
Jiang, T.
|
|
|
30 |
S2 |
p. ii69-ii70
|
artikel
|
| 70 |
Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON
|
Brückl, W.
|
|
|
30 |
S2 |
p. ii49
|
artikel
|
| 71 |
Electromagnetic navigation bronchoscopy in the European cohort of the prospective, multicenter NAVIGATE study
|
Lau, K.
|
|
|
30 |
S2 |
p. ii26
|
artikel
|
| 72 |
Endobronchial surgery and photodynamic therapy for early central lung cancer treatment
|
Pirogov, S.S.
|
|
|
30 |
S2 |
p. ii29
|
artikel
|
| 73 |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi, F.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 74 |
Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
|
Paz-Ares, L.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 75 |
EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer
|
Lindsay, C.R.
|
|
|
30 |
S2 |
p. ii7
|
artikel
|
| 76 |
EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy
|
Prelaj, A.
|
|
|
30 |
S2 |
p. ii59
|
artikel
|
| 77 |
ERGR-TKIs combined with chemotherapy delays intracranial progression in EGFR-mutant lung adenocarcinoma patients
|
Li, C.
|
|
|
30 |
S2 |
p. ii69
|
artikel
|
| 78 |
European Lung Cancer Congress (ELCC) 2019 Organisation and Officers
|
|
|
|
30 |
S2 |
p. ix-x
|
artikel
|
| 79 |
European Society for Radiotherapy and Oncology (ESTRO)
|
|
|
|
30 |
S2 |
p. viii
|
artikel
|
| 80 |
European Society of Thoracic Surgeons (ESTS)
|
|
|
|
30 |
S2 |
p. viii
|
artikel
|
| 81 |
European Thoracic Oncology Platform (ETOP)
|
|
|
|
30 |
S2 |
p. viii
|
artikel
|
| 82 |
Evaluation of a care path for patients with lung tumors and co-existing interstitial lung disease
|
Ronden-Kianoush, M.I.
|
|
|
30 |
S2 |
p. ii21
|
artikel
|
| 83 |
Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer
|
Thottian, A.G.F.
|
|
|
30 |
S2 |
p. ii76
|
artikel
|
| 84 |
Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative
|
Sørensen, J.B.
|
|
|
30 |
S2 |
p. ii16-ii17
|
artikel
|
| 85 |
Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers
|
Durendez-Saez, E.
|
|
|
30 |
S2 |
p. ii10-ii11
|
artikel
|
| 86 |
Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India
|
Jat, R.R.
|
|
|
30 |
S2 |
p. ii24
|
artikel
|
| 87 |
External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy
|
Käsmann, L.
|
|
|
30 |
S2 |
p. ii23
|
artikel
|
| 88 |
Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study
|
Kirita, K.
|
|
|
30 |
S2 |
p. ii76
|
artikel
|
| 89 |
Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients
|
Abdulla, D.S.
|
|
|
30 |
S2 |
p. ii64-ii65
|
artikel
|
| 90 |
Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
|
Mok, T.S.K
|
|
|
30 |
S2 |
p. i38
|
artikel
|
| 91 |
FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC
|
Nogova, L.
|
|
|
30 |
S2 |
p. ii67
|
artikel
|
| 92 |
FOXP3Δ3, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer
|
Jia, H.
|
|
|
30 |
S2 |
p. ii5-ii6
|
artikel
|
| 93 |
Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer
|
Sow, M.L.
|
|
|
30 |
S2 |
p. ii50
|
artikel
|
| 94 |
Genetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals
|
Dimitrakopoulos, F.-I.D.
|
|
|
30 |
S2 |
p. ii12
|
artikel
|
| 95 |
Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study
|
Pérol, M.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 96 |
Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells
|
Liu, Y.
|
|
|
30 |
S2 |
p. ii12
|
artikel
|
| 97 |
Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis
|
Taugner, J.
|
|
|
30 |
S2 |
p. ii35
|
artikel
|
| 98 |
High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)
|
Cordoba Ortega, J.F.
|
|
|
30 |
S2 |
p. ii30
|
artikel
|
| 99 |
High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma
|
Liang, L.
|
|
|
30 |
S2 |
p. ii12
|
artikel
|
| 100 |
Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer
|
Rocha, P.
|
|
|
30 |
S2 |
p. ii30
|
artikel
|
| 101 |
Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse
|
Pavan, A.
|
|
|
30 |
S2 |
p. ii58-ii59
|
artikel
|
| 102 |
Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features
|
Kokkotou, E.
|
|
|
30 |
S2 |
p. ii5
|
artikel
|
| 103 |
Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models
|
Weinberg, U.
|
|
|
30 |
S2 |
p. ii2-ii3
|
artikel
|
| 104 |
Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice
|
Faehling, M.
|
|
|
30 |
S2 |
p. ii60
|
artikel
|
| 105 |
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)
|
Ferrara, R.
|
|
|
30 |
S2 |
p. ii7-ii8
|
artikel
|
| 106 |
Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma
|
Januszewski, A.
|
|
|
30 |
S2 |
p. ii1
|
artikel
|
| 107 |
Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC
|
Ouwens, M.
|
|
|
30 |
S2 |
p. ii31
|
artikel
|
| 108 |
Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC
|
Hoffmann, M.
|
|
|
30 |
S2 |
p. ii36
|
artikel
|
| 109 |
Impact of underlying pulmonary diseases on treatment outcomes in early stage non-small cell lung cancer treated with definitive radiotherapy
|
Kim, H.
|
|
|
30 |
S2 |
p. ii27
|
artikel
|
| 110 |
Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)
|
Scheffler, M.
|
|
|
30 |
S2 |
p. ii55
|
artikel
|
| 111 |
Impacts of HDAC2 inhibition on lung cancer treatment
|
Yeh, Y.-T.
|
|
|
30 |
S2 |
p. ii11
|
artikel
|
| 112 |
Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center
|
Leventakos, K.
|
|
|
30 |
S2 |
p. ii74
|
artikel
|
| 113 |
Implementation of organized lung cancer screening program in Korea
|
Kim, Y.
|
|
|
30 |
S2 |
p. ii14
|
artikel
|
| 114 |
Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center
|
Tsiouprou, I.
|
|
|
30 |
S2 |
p. ii75
|
artikel
|
| 115 |
Implications for UK practice of the use of durvalumab in stage III NSCLC
|
Iqbal, M.S.
|
|
|
30 |
S2 |
p. ii36
|
artikel
|
| 116 |
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
|
Reck, M.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 117 |
IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy
|
Peters, S.
|
|
|
30 |
S2 |
p. ii30
|
artikel
|
| 118 |
Index
|
|
|
|
30 |
S2 |
p. ii81
|
artikel
|
| 119 |
Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape
|
Naish, P.
|
|
|
30 |
S2 |
p. ii74
|
artikel
|
| 120 |
Initial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC
|
Lang, D.
|
|
|
30 |
S2 |
p. ii59
|
artikel
|
| 121 |
International Association for the Study of Lung Cancer (IASLC)
|
|
|
|
30 |
S2 |
p. vii
|
artikel
|
| 122 |
Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia
|
McCann, K.
|
|
|
30 |
S2 |
p. ii19
|
artikel
|
| 123 |
Is there any prognostic significance of the level of change in SUVmax after SBRT in patients with early stage NSCLC?
|
Yaprak, G.
|
|
|
30 |
S2 |
p. ii28
|
artikel
|
| 124 |
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC
|
Cinausero, M.
|
|
|
30 |
S2 |
p. ii55-ii56
|
artikel
|
| 125 |
Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China
|
Wang, S.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 126 |
Lung resection for cancer in patients with heart disease: Management and postoperative outcome
|
Caushi, F.S.
|
|
|
30 |
S2 |
p. ii29
|
artikel
|
| 127 |
Lung tumorspheres as a drug screening platform against cancer stem cells
|
Herreros Pomares, A.
|
|
|
30 |
S2 |
p. ii8
|
artikel
|
| 128 |
Management of cN2 NSCLC patients treated with radical radiotherapy: Relapse with or without brain metastases
|
McKay, F.
|
|
|
30 |
S2 |
p. ii70
|
artikel
|
| 129 |
Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial
|
Galli, G.
|
|
|
30 |
S2 |
p. ii68
|
artikel
|
| 130 |
Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC)
|
Di Noia, V.
|
|
|
30 |
S2 |
p. ii60
|
artikel
|
| 131 |
Multi-centre analysis of cardiac events following radical radiotherapy for lung cancer
|
Sun, F.
|
|
|
30 |
S2 |
p. ii27
|
artikel
|
| 132 |
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
|
Wagener-Ryczek, S.
|
|
|
30 |
S2 |
p. ii51
|
artikel
|
| 133 |
New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer
|
Fassunke, J.
|
|
|
30 |
S2 |
p. ii51
|
artikel
|
| 134 |
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
|
Owonikoko, T.K.
|
|
|
30 |
S2 |
p. ii77
|
artikel
|
| 135 |
Nomogram for patients with stage I small cell lung cancer: A competing risk analysis
|
Liu, J.
|
|
|
30 |
S2 |
p. ii22
|
artikel
|
| 136 |
Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor
|
Cipriano, É.
|
|
|
30 |
S2 |
p. ii75
|
artikel
|
| 137 |
Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study
|
Gundu, N.
|
|
|
30 |
S2 |
p. ii20
|
artikel
|
| 138 |
Notable variation of molecular testing in metastatic lung cancer in the Netherlands
|
Kuijpers, C.
|
|
|
30 |
S2 |
p. ii1-ii2
|
artikel
|
| 139 |
NSCLC stages IIa-IIIc: Tumor related IGRT yields better local control than kV-guidance to anatomic structures
|
Zehentmayr, F.
|
|
|
30 |
S2 |
p. ii63
|
artikel
|
| 140 |
Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study
|
Ding, Z.-Y.
|
|
|
30 |
S2 |
p. ii49-ii50
|
artikel
|
| 141 |
Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts
|
Yang, J.C.-H.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 142 |
Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study
|
Ahn, M.-J.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 143 |
PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
|
Girard, N.
|
|
|
30 |
S2 |
p. ii37
|
artikel
|
| 144 |
Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors
|
Dumoulin, D.
|
|
|
30 |
S2 |
p. ii7
|
artikel
|
| 145 |
Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)
|
Garassino, M.C.
|
|
|
30 |
S2 |
p. ii78
|
artikel
|
| 146 |
Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy
|
Eze, C.
|
|
|
30 |
S2 |
p. ii36
|
artikel
|
| 147 |
PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype
|
Zhang, Y.
|
|
|
30 |
S2 |
p. ii52
|
artikel
|
| 148 |
PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC
|
Qin, Y.
|
|
|
30 |
S2 |
p. ii60
|
artikel
|
| 149 |
Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
|
Prelaj, A.
|
|
|
30 |
S2 |
p. ii58
|
artikel
|
| 150 |
Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)
|
Martinez Kareaga, M.
|
|
|
30 |
S2 |
p. ii63
|
artikel
|
| 151 |
Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)
|
Mehta, M.
|
|
|
30 |
S2 |
p. ii70-ii71
|
artikel
|
| 152 |
Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
|
Shimokawa, M.
|
|
|
30 |
S2 |
p. ii66
|
artikel
|
| 153 |
Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations
|
Creelan, B.C.
|
|
|
30 |
S2 |
p. ii31-ii32
|
artikel
|
| 154 |
Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts)
|
Aldea, M.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 155 |
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy
|
Bonanno, L.
|
|
|
30 |
S2 |
p. ii9
|
artikel
|
| 156 |
Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study
|
Xu, C.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 157 |
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
|
Juan Vidal, O.J.
|
|
|
30 |
S2 |
p. ii9-ii10
|
artikel
|
| 158 |
Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)
|
Planchard, D.
|
|
|
30 |
S2 |
p. ii32-ii33
|
artikel
|
| 159 |
Previous exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC
|
Zhou, F.
|
|
|
30 |
S2 |
p. ii62
|
artikel
|
| 160 |
Primary mucinous carcinomas of the lung: Clinical characteristics and treatment outcomes
|
Thottian, A.G.F.
|
|
|
30 |
S2 |
p. ii76
|
artikel
|
| 161 |
Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns
|
Hu, F.
|
|
|
30 |
S2 |
p. ii35
|
artikel
|
| 162 |
Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies
|
Schett, A.
|
|
|
30 |
S2 |
p. ii58
|
artikel
|
| 163 |
Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer
|
Kotsantis, I.
|
|
|
30 |
S2 |
p. ii10
|
artikel
|
| 164 |
Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer
|
Rapoport, B.L.
|
|
|
30 |
S2 |
p. ii61
|
artikel
|
| 165 |
Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy
|
Gennen, K.
|
|
|
30 |
S2 |
p. ii11
|
artikel
|
| 166 |
Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience
|
Godara, S.K.
|
|
|
30 |
S2 |
p. ii74
|
artikel
|
| 167 |
Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries
|
Akter, M.S.
|
|
|
30 |
S2 |
p. ii19
|
artikel
|
| 168 |
Racial disparities in characteristics and prognosis in Asian versus white patients receiving atezolizumab: An ancillary analysis of POPLAR and OAK studies
|
Qian, J.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 169 |
Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation
|
Wadhwa, S.
|
|
|
30 |
S2 |
p. ii20
|
artikel
|
| 170 |
Radiomic-based quantitative CT analysis to predict the invasiveness of pure ground-glass lung adenocarcinoma
|
Xv, F.
|
|
|
30 |
S2 |
p. ii26-ii27
|
artikel
|
| 171 |
RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)
|
Paz-Ares, L.
|
|
|
30 |
S2 |
p. ii67
|
artikel
|
| 172 |
Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients
|
Hochmair, M.J.
|
|
|
30 |
S2 |
p. ii23
|
artikel
|
| 173 |
Real-world experience of ALK positive NSCLC from India
|
Malhotra, M.
|
|
|
30 |
S2 |
p. ii64
|
artikel
|
| 174 |
Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States
|
Pan, X.
|
|
|
30 |
S2 |
p. ii52-ii53
|
artikel
|
| 175 |
Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database
|
Girard, N.
|
|
|
30 |
S2 |
p. ii34
|
artikel
|
| 176 |
Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy
|
Altini, M.
|
|
|
30 |
S2 |
p. ii63-ii64
|
artikel
|
| 177 |
REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors
|
Fabrizio, F.P.
|
|
|
30 |
S2 |
p. ii5
|
artikel
|
| 178 |
Reduced-, and no-dose thin-section radiologic examinations: Comparison of capability for nodule detection in patients having pulmonary nodules
|
Tang, W.
|
|
|
30 |
S2 |
p. ii18
|
artikel
|
| 179 |
Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire
|
Sharma, D.
|
|
|
30 |
S2 |
p. ii49
|
artikel
|
| 180 |
Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion
|
Zhang, J.
|
|
|
30 |
S2 |
p. ii50
|
artikel
|
| 181 |
Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy
|
Dumoulin, D.
|
|
|
30 |
S2 |
p. ii57
|
artikel
|
| 182 |
Research Index
|
|
|
|
30 |
S2 |
p. ii82
|
artikel
|
| 183 |
Retrospective study about lung carcinoid: Our experience in a Spanish hospital
|
Cabrero, D.S.
|
|
|
30 |
S2 |
p. ii75
|
artikel
|
| 184 |
Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
|
Roeper, J.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 185 |
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
|
Drosslerová, M.
|
|
|
30 |
S2 |
p. ii3
|
artikel
|
| 186 |
Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study
|
Zhao, Y.
|
|
|
30 |
S2 |
p. ii54
|
artikel
|
| 187 |
Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042
|
Nosaki, K.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 188 |
Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study
|
Horinouchi, H.
|
|
|
30 |
S2 |
p. ii56-ii57
|
artikel
|
| 189 |
Safety meta-analysis of clinical trials delivering TTFields to the upper torso
|
Ceresoli, G.L.
|
|
|
30 |
S2 |
p. ii73
|
artikel
|
| 190 |
Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis
|
Büntzel, J.
|
|
|
30 |
S2 |
p. ii76
|
artikel
|
| 191 |
STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma
|
Ceresoli, G.L.
|
|
|
30 |
S2 |
p. ii72
|
artikel
|
| 192 |
Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival
|
Kroeze, S.G.C.
|
|
|
30 |
S2 |
p. ii63
|
artikel
|
| 193 |
Table of Contents
|
|
|
|
30 |
S2 |
p. iv
|
artikel
|
| 194 |
Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative
|
Snee, M.
|
|
|
30 |
S2 |
p. ii14-ii15
|
artikel
|
| 195 |
The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis
|
Zhu, Y.
|
|
|
30 |
S2 |
p. ii5
|
artikel
|
| 196 |
The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma
|
Huang, Q.
|
|
|
30 |
S2 |
p. ii2
|
artikel
|
| 197 |
The effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients: Subgroup analyses of the NVALT-11/DLCRG-02 study
|
Witlox, W.J.A.
|
|
|
30 |
S2 |
p. ii33-ii34
|
artikel
|
| 198 |
The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation
|
Li, J.
|
|
|
30 |
S2 |
p. ii49
|
artikel
|
| 199 |
The European Society for Medical Oncology (ESMO)
|
|
|
|
30 |
S2 |
p. vi
|
artikel
|
| 200 |
The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies
|
Kuo, T.-C.
|
|
|
30 |
S2 |
p. ii13
|
artikel
|
| 201 |
The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact
|
Shemesh, R.
|
|
|
30 |
S2 |
p. ii4
|
artikel
|
| 202 |
The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations
|
Wang, W.
|
|
|
30 |
S2 |
p. ii3-ii4
|
artikel
|
| 203 |
The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)
|
Gagliasso, M.
|
|
|
30 |
S2 |
p. ii29
|
artikel
|
| 204 |
The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC
|
Käsmann, L.
|
|
|
30 |
S2 |
p. ii36
|
artikel
|
| 205 |
Thoracic ultrasound can be a trustable tool in untouchable lung nodule surgery
|
Zhang, H.
|
|
|
30 |
S2 |
p. ii28
|
artikel
|
| 206 |
Thromboembolic events in advanced non-small cell lung cancer
|
Srinivasalu, V.K.
|
|
|
30 |
S2 |
p. ii48-ii49
|
artikel
|
| 207 |
Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
|
Prelaj, A.
|
|
|
30 |
S2 |
p. ii34
|
artikel
|
| 208 |
Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC)
|
McSorley, L.M.
|
|
|
30 |
S2 |
p. ii23-ii24
|
artikel
|
| 209 |
Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer
|
Chen, X.
|
|
|
30 |
S2 |
p. ii29
|
artikel
|
| 210 |
Title Page
|
|
|
|
30 |
S2 |
p. v
|
artikel
|
| 211 |
Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)
|
Lin, M.M.
|
|
|
30 |
S2 |
p. ii48
|
artikel
|
| 212 |
Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark
|
Green, A.
|
|
|
30 |
S2 |
p. ii34
|
artikel
|
| 213 |
Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice
|
Sebastian, M.
|
|
|
30 |
S2 |
p. ii24
|
artikel
|
| 214 |
Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice
|
Frueh, M.
|
|
|
30 |
S2 |
p. ii65
|
artikel
|
| 215 |
Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative
|
Ekman, S.
|
|
|
30 |
S2 |
p. ii17
|
artikel
|
| 216 |
Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative
|
Soares, M.A.S.
|
|
|
30 |
S2 |
p. ii15-ii16
|
artikel
|
| 217 |
TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor
|
Cordoba Ortega, J.F.
|
|
|
30 |
S2 |
p. ii5
|
artikel
|
| 218 |
Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
|
Jermann, P.
|
|
|
30 |
S2 |
p. ii59
|
artikel
|
| 219 |
Tumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study
|
Weinberg, U.
|
|
|
30 |
S2 |
p. ii68
|
artikel
|
| 220 |
Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
|
Li, C.
|
|
|
30 |
S2 |
p. ii50
|
artikel
|
| 221 |
Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
|
Damhuis, R.
|
|
|
30 |
S2 |
p. ii27-ii28
|
artikel
|
| 222 |
Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model
|
Yu, J.
|
|
|
30 |
S2 |
p. ii23
|
artikel
|
Tijdschrift beschrijving